Immunogenicity of three recombinant hepatitis B vaccines administered to students in three doses containing half the antigen amount routinely used for adult vaccination

We evaluated the immunogenicity of three recombinant hepatitis B vaccines, one Brazilian (Butang, Instituto Butantan) and two Korean vaccines (Euvax-B, LG Chemical Ltd. and Hepavax-Gene, Greencross Vaccine Corp.), administered intramuscularly to students aged 17 to 19 years in three 10-µg doses (corresponding to half the amount of antigen routinely used for adult vaccination) at intervals of one month between the first and second dose, and of four months between the second and third dose. A total of 316 students non-reactive for any serological marker of hepatitis B virus infection were vaccinated: 77 (24.4%) with the Butang vaccine, 71 (22.5%) with Euvax-B, 85 (26.9%) with Hepavax-Gene and, for comparison, 83 (26.2%) with Engerix-B (GlaxoSmithKline), whose efficacy in young adults at the dose used here has been confirmed in previous studies. Similar seroconversion rates (anti-HBs > 10 mIU/mL about one month after application of the third dose) were obtained for the Butang, Euvax-B, Hepavax-Gene and Engerix-B vaccines (96.2%, 98.6%, 96.5% and 97.6%, respectively). The frequency of good responders (anti-HBs > 100 mIU/mL) was also similar among students receiving the four vaccines (85.8%, 91.6%, 89.4% and 89.2%, respectively). The geometric mean titers (GMT) of anti-HBs about one month after the third dose obtained with these vaccines were 727.78 ± 6.46 mIU/mL, 2009.09 ± 7.16 mIU/mL, 1729.82 ± 8.85 mIU/mL and 2070.14 ± 11.69 mIU/mL, respectively. The GMT of anti-HBs induced by the Euvax-B and Engerix-B vaccines were higher than those obtained with the Butang vaccine (p < 0.05); this difference was not significant when comparing the other vaccines two-by-two. No spontaneous adverse effects attributable to the application of any dose of the four vaccines were reported.

Download Full-text

Seroconversion after Recombinant Hepatitis B Vaccination

Journal of Medicine ◽

10.3329/jom.v11i2.5461 ◽

1970 ◽

Vol 11 (2) ◽

pp. 143-150 ◽

Cited By ~ 3

Author(s):

Abhijit Guho ◽

Md Abdul Ahad ◽

Md Abdus Salam ◽

Md Abdul Alim ◽

AKM Enamul Haque ◽

...

Keyword(s):

Hepatitis B Virus ◽

Virus Infection ◽

Hepatitis B ◽

Hepatitis B Vaccine ◽

Hepatitis B Virus Infection ◽

Recombinant Hepatitis ◽

Protective Level ◽

Significant Difference ◽

B Virus ◽

Study Population

Background: Hepatitis B virus infection is an important public health problem with significant morbidity andmortality. Recombinant hepatitis B vaccine for the prevention of hepatitis B virus infection is in practice in differentparts of the world since its availability in 1986. Government of Bangladesh has also included hepatitis B vaccine inEPI schedule since 2005.Materials and methods: This study was carried out to assess the seroconversion status among hepatitis Bvaccinated individuals. A total of 190 individuals including 150 vaccinated persons and 40 non-vaccinated apparentlyhealthy individuals were included as study population. Sources of vaccinated persons were from both EPI and non-EPI schedule of vaccination. Age and sex matched non-vaccinated individuals served as controls for the study. Allindividuals constituting the study population were screened for HBsAg by Immunochromatographic strip test andonly HBsAg-negative persons were included for estimation of their anti-HBs titer.Results: Out of 150 vaccinated individuals, 133(88.67%) were found to have anti-HBs titer in the protective level(>10 IU/L), while 17(11.33%) individuals had anti-HBs titer below the protective level (<10 IU/L). All non-vaccinatedcontrols had anti-HBs titers below the protective level. Regarding immune response developed among vaccinatedindividuals, 67.78%, 23.33% and 8.89% were good-responders, hypo-responders and non-responders respectively.Mean titer of anti-HBs was found significantly higher among recipients who received booster dose than those whoreceived 3 doses schedule (863.39 IU/L vs. 262.40 IU/L), indicating high antibody titer develops after booster dose.Vaccinated group included 85 (56.67%) men and 65 (43.33%) women with protective level of anti-HBs titer foundin 85.88% male and 92.31% female individuals. There was no significant difference of anti-HBs titer between maleand female (p>0.05). Vaccinated individuals from lower socioeconomic condition have had comparatively low rateof protective antibody than people from middle and upper classes.Conclusion: Recombinant HB vaccine induces good level of protective immunity among vaccinated persons.Keywords: Hepatitis B; hepatitis B vaccine; seroconversion; BangladeshDOI: 10.3329/jom.v11i2.5461J MEDICINE 2010; 11 : 143-150

Download Full-text

Role of Booster Dose on Antibody Titer after Recombinant Hepatitis B Vaccination

Journal of Medicine ◽

10.3329/jom.v10i2.2817 ◽

1970 ◽

Vol 10 (2) ◽

pp. 67-76 ◽

Cited By ~ 2

Author(s):

Md Abdul Ahad ◽

Md Abdul Alim ◽

Abhijit Guho ◽

Quazi Tarikul Islam ◽

Khan Abul Kalam Azad

Keyword(s):

Hepatitis B Virus ◽

Virus Infection ◽

Hepatitis B ◽

Booster Dose ◽

Hepatitis B Vaccination ◽

Hepatitis B Virus Infection ◽

Recombinant Hepatitis ◽

Protective Level ◽

B Virus ◽

Study Population

Hepatitis B virus infection is an important public health problem with significant morbidity and mortality. Recombinant hepatitis B vaccination for the prevention of hepatitis B virus infection is in practice in different parts of the world since its availability in 1986. Government of Bangladesh has also included hepatitis B vaccine in EPI schedule since 2005. This study was carried out to assess the seroconversion status among hepatitis B vaccinated individuals. A total of 190 individuals including 150 vaccinated persons and 40 non-vaccinated apparently healthy individuals were included as study population. Sources of vaccinated persons were from both EPI and non-EPI schedule of vaccination. Age and sex matched non-vaccinated individuals served as controls for the study. All individuals constituting the study population were screened for HBsAg by Immunochromatographic strip test and only HBsAg-negative persons were included for estimation of their anti-HBs titer. Out of 150 vaccinated individuals, 133(88.67%) were found to have anti-HBs titer in the protective level (e"10 IU/L), while 17(11.33%) individuals had anti-HBs titer below the protective level (<10 IU/L). All non-vaccinated controls had anti- HBs titers below the protective level. Immune response developed among vaccinated individuals, 67.78%, 23.33% and 8.89% were good-responders, hypo-responders and non-responders respectively. Mean titer of anti-HBs was found significantly higher among recipients who received booster dose than those who received 3 doses schedule (863.39 IU/L vs. 262.40 IU/L), indicating high antibody titer develops after booster dose. Vaccinated group included 85 (56.67%) men and 65 (43.33%) women with protective level of anti-HBs titer found in 85.88% male and 92.31% female individuals. doi: 10.3329/jom.v10i2.2817 J MEDICINE 2009; 10 : 67-76

Download Full-text

Effect of Revaccination Using Different Schemes among Adults with Low or Undetectable Anti-HBs Titers after Hepatitis B Virus Vaccination

Clinical and Vaccine Immunology ◽

10.1128/cvi.00064-10 ◽

2010 ◽

Vol 17 (10) ◽

pp. 1548-1551 ◽

Cited By ~ 6

Author(s):

Chao-Shuang Lin ◽

Shi-Bin Xie ◽

Jing Liu ◽

Zhi-Xin Zhao ◽

Yu-Tian Chong ◽

...

Keyword(s):

Hepatitis B Virus ◽

Hepatitis B ◽

Geometric Mean ◽

Recombinant Vaccine ◽

Recombinant Hepatitis ◽

Healthy Male ◽

Hbv Vaccine ◽

Hbv Vaccination ◽

Conversion Rates ◽

B Virus

ABSTRACT Our objective was to investigate the effect of various reimmunization schemes for hepatitis B in adults with low or undetectable anti-HBs titers. Over 2 years, 10 μg of Saccharomyces cerevisiae-recombinant hepatitis B virus (HBV) vaccine (synthesized in China) was used in at least one standardized scheme to immunize 2,310 healthy male and nonpregnant female adults. Of these, 240 subjects tested negative for hepatitis B markers. These 240 subjects were equally divided into 4 groups. The first group, designated Engerix-40, was revaccinated with 40 μg Engerix-B; the second, Engerix-20, was revaccinated with 20 μg Engerix-B; the third, Chinese-20, was revaccinated with 20 μg Chinese-made yeast-recombinant vaccine; and the last group, Chinese-10, was revaccinated with 10 μg Chinese-made yeast-recombinant vaccine. Blood samples were collected before and 1, 2, 8, and 12 months after the first injection. The anti-HBs-positive conversion rates of the Engerix-40, Engerix-20, and Chinese-20 groups were higher than that of the Chinese-10 group (P < 0.01). Over time, the anti-HBs conversion rate increased in all groups, but values were significantly different from those for the other groups only in the Chinese-10 group (P < 0.001). The anti-HBs geometric mean titers (GMTs) of the Engerix-40, Engerix-20, and Chinese-20 groups were higher than in the Chinese-10 group (P < 0.05). Increased doses raise and maintain anti-HBs titers in subjects with low or undetectable titers after HBV vaccination.

Download Full-text

Persistence of Protection Against Hepatitis B Virus Infection Among Adolescents Vaccinated With Recombinant Hepatitis B Vaccine Beginning at Birth

The Pediatric Infectious Disease Journal ◽

10.1097/inf.0b013e31817702ba ◽

2008 ◽

Vol 27 (10) ◽

pp. 881-885 ◽

Cited By ~ 81

Author(s):

Stephanie R. Bialek ◽

William A. Bower ◽

Ryan Novak ◽

Louisa Helgenberger ◽

Steven B. Auerbach ◽

...

Keyword(s):

Hepatitis B Virus ◽

Virus Infection ◽

Hepatitis B ◽

Hepatitis B Vaccine ◽

Hepatitis B Virus Infection ◽

Recombinant Hepatitis ◽

B Virus

Download Full-text

Occult hepatitis B virus infection in maintenance hemodialysis patients: prevalence and mutations in “a” determinant

10.21203/rs.2.14206/v1 ◽

2019 ◽

Author(s):

Yun Tang ◽

Xiangqin Liu ◽

Daqing Hong ◽

Xiangheng Lu ◽

Qiang He ◽

...

Keyword(s):

Hepatitis B Virus ◽

Virus Infection ◽

Hepatitis B ◽

Real Time Pcr ◽

Nested Pcr ◽

Hbv Dna ◽

The Other ◽

Maintenance Hemodialysis ◽

Hepatitis B Virus Infection ◽

B Virus

Abstract Background：Occult hepatitis B virus infection (OBI) is rare and its diagnosis is often overlooked, but there is still a risk of HBV transmission. To analysis the prevalence of OBI among maintenance hemodialysis (MHD) patients in Sichuan Provincial People’s Hospital, the molecular biological characteristics of OBI and the mutation of “a” determinant were investigated. Method: A total of 330 patients undergoing hemodialysis at Sichuan Provincial People’s Hospital and its satellite dialysis units were tested for HBV markers by ELISA. HBV-DNA was detected by real-time PCR in patients with HBsAg negative/ HBcAb positive to investigate the prevalence of OBI. For plasma samples with persistent HBV DNA positive, the S gene was determined by nested PCR, and the sequence of gene mutation was compared with the standard sequence. Result: Among 330 patients, ages range from 27 to 95 with a mean of 60.66 years old and majority of patients (57.6%) > 60 years old. Serum from 165 of 180 HBsAg negative/HBcAb positive individuals were tested for HBV DNA by real-time PCR. 7 of 165 patients had low level of HBV DNA. Of those, 5 individuals were both HBcAb and HBsAb positive, and 2 individuals were HBcAb positive alone. After 2 years follow-up, 2 individuals with HBcAb positive alone were both tested HBV DNA again, but the other patients were not. Serum from the 2 patients were used nested PCR to confirm the genotype and the mutation of S gene. We found they both were genotype B. Amino acid sequencing confirmed that one had no mutations and the other one had Q128R, T131N, M133S, F134L and D144E mutants in “a” determinant. Conclusion: Chronic HBV infection was 7.3% (24/330) and OBI was 2.1% (7/330) in our hospital hemodialysis center. The genotype of patients with OBI were genotype B. Mutations of Q128R，T131N，M133S，F134L and D144E might be the potential sites associated with OBI.

Download Full-text

Is There any Difference in Antibody Titer Between Children and Adults after Recombinant Hepatitis B Vaccination?

TAJ Journal of Teachers Association ◽

10.3329/taj.v21i1.3210 ◽

1970 ◽

Vol 21 (1) ◽

pp. 1-11

Author(s):

M Abdul Ahad ◽

M Abdul Alim ◽

Abhiji Guho ◽

ARM Saifuddin Ekram

Keyword(s):

Hepatitis B Virus ◽

Hepatitis B ◽

Antibody Titer ◽

Booster Dose ◽

Hepatitis B Vaccination ◽

Hepatitis B Virus Infection ◽

Recombinant Hepatitis ◽

Protective Level ◽

B Virus ◽

Study Population

Hepatitis B virus infection is an important public health problem with significant morbidity and mortality. Recombinant hepatitis B vaccine for the prevention of hepatitis B virus infection is in practice in different parts of the world since its availability in 1986. Government of Bangladesh has also included hepatitis B vaccine in EPI schedule since 2005. This study was carried out to assess the seroconversion status among hepatitis B vaccinated individuals. A total of 190 individuals including 150 vaccinated persons and 40 non-vaccinated apparently healthy individuals were included as study population. Sources of vaccinated persons were from both EPI and non-EPI schedule of vaccination. Age and sex matched non-vaccinated individuals served as controls for the study. All individuals constituting the study population were screened for HBsAg by Immunochromatographic strip test and only HBsAg-negative persons were included for estimation of their anti-HBs titer. Out of 150 vaccinated individuals, 133(88.67%) were found to have anti-HBs titer in the protective level (≥10 IU/L), while 17(11.33%) individuals had anti-HBs titer below the protective level (<10 IU/L). All non-vaccinated controls had anti-HBs titers below the protective level. Regarding immune response developed among vaccinated individuals, 67.78%, 23.33% and 8.89% were good-responders, hypo-responders and nonresponders respectively. Mean titer of anti-HBs was found significantly higher among recipients who received booster dose than those who received 3 doses schedule (863.39 IU/L vs. 262.40 IU/L), indicating high antibody titer develops after booster dose. Vaccinated group included 85 (56.67%) men and 65 (43.33%) women with protective level of anti-HBs titer found in 85.88% male and 92.31% female individuals. Vaccinated individuals from lower socioeconomic condition have had comparatively low rate of protective antibody than people from middle and upper classes. Recombinant HB vaccine induces good level of protective immunity among vaccinated persons. The present study showed that the proportion of adults (93.33%) developed level of protective antibody titer was higher than that of children (83.33%). It indicates that there is difference of antibody titer between children and adults after recombinant Hepatitis B vaccination. doi: 10.3329/taj.v21i1.3210 TAJ 2008; 21(1): 1-11

Download Full-text